Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Liabilities from Discontinued Operations (2022 - 2024)

Historic Liabilities from Discontinued Operations for Mimedx (MDXG) over the last 3 years, with Q2 2024 value amounting to $217000.0.

  • Mimedx's Liabilities from Discontinued Operations changed N/A to $217000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $217000.0, marking a year-over-year change of. This contributed to the annual value of $1.4 million for FY2023, which is 858.69% down from last year.
  • Per Mimedx's latest filing, its Liabilities from Discontinued Operations stood at $217000.0 for Q2 2024.
  • In the past 5 years, Mimedx's Liabilities from Discontinued Operations ranged from a high of $1.5 million in Q4 2022 and a low of $217000.0 during Q2 2024
  • Over the past 3 years, Mimedx's median Liabilities from Discontinued Operations value was $848000.0 (recorded in 2023), while the average stood at $848000.0.
  • The largest annual percentage gain for Mimedx's Liabilities from Discontinued Operations in the last 5 years was 858.69% (2023), contrasted with its biggest fall of 858.69% (2023).
  • Over the past 3 years, Mimedx's Liabilities from Discontinued Operations (Quarter) stood at $1.5 million in 2022, then decreased by 8.59% to $1.4 million in 2023, then crashed by 83.95% to $217000.0 in 2024.
  • Its Liabilities from Discontinued Operations stands at $217000.0 for Q2 2024, versus $344000.0 for Q1 2024 and $1.4 million for Q4 2023.